Esperion Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Esperion Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Esperion Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $396M, a 12.3% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $396M +$43.5M +12.3% Dec 31, 2023 10-K 2024-02-27
Q4 2022 $352M +$68M +23.9% Dec 31, 2022 10-K 2024-02-27
Q4 2021 $284M +$81.3M +40.1% Dec 31, 2021 10-K 2023-02-21
Q4 2020 $203M +$28.6M +16.4% Dec 31, 2020 10-K 2022-02-22
Q4 2019 $174M +$22M +14.5% Dec 31, 2019 10-K 2021-02-23
Q4 2018 $152M +$52.3M +52.4% Dec 31, 2018 10-K 2020-02-27
Q4 2017 $99.8M +$24.6M +32.7% Dec 31, 2017 10-K 2019-02-28
Q4 2016 $75.3M +$24.7M +48.8% Dec 31, 2016 10-K 2018-02-20
Q4 2015 $50.6M +$16.4M +47.8% Dec 31, 2015 10-K 2017-02-22
Q4 2014 $34.2M +$11.4M +50% Dec 31, 2014 10-K 2016-02-25
Q4 2013 $22.8M +$8.45M +58.9% Dec 31, 2013 10-K 2015-03-10
Q4 2012 $14.4M Dec 31, 2012 10-K 2014-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.